C Banfi, P Eriksson, G Giandomenico, L … - Diabetes, 2001 - Am Diabetes Assoc Impairment of the fibrinolytic system, caused primarily by increases in the
plasma levels of plasminogen activator inhibitor (PAI) type 1, are frequently
found in diabetes and the insulin-resistance syndrome. Among the factors ... Cited by 76 - Related articles - BL Direct - All 4 versions
HE Grenett, RL Benza, XN Li, ML Aikens, JR … - Thrombosis and haemostasis, 1999 - ncbi.nlm.nih.gov Patients with non-insulin-dependent diabetes mellitus frequently have been
associated with elevation in plasma levels of PAI-1. Part of the variations in
individual plasma PAI-1 levels have been attributed to variations in the ... Cited by 21 - Related articles - BL Direct - All 2 versions
TK Nordt, C Bode, BE Sobel - Diabetologia, 2001 - Springer The incidence of coronary artery disease is markedly increased in patients with
insulin resistance such as ... Stimulation in vivo of expression of
intra-abdominal adipose tissue ... TKNordt 1 , C.Bode 1 , BESobel 2 Cited by 31 - Related articles - BL Direct - All 3 versions
- ►nih.gov [PDF] F Samad, M Pandey, PA Bell, DJ Loskutoff - Molecular Medicine, 2000 - pubmedcentral.nih.gov Background: Although the association between in- sulin resistance and
cardiovascular risk is well es- tablished, the underlying molecular mechanisms
are poorly understood. The antifibrinolytic molecule plasminogen activator ... Cited by 74 - Related articles - BL Direct - All 5 versions
- ►ahajournals.org C Banfi, L Mussoni, P Rise, MG Cattaneo, L … - Circulation research, 1999 - Am Heart Assoc Abstract—In normal subjects and in patients with cardiovascular disease,
plasma triglycerides are positively correlated with plasminogen activator
inhibitor type 1 (PAI-1) levels. Moreover, in vitro studies indicate that ... Cited by 39 - Related articles - BL Direct - All 7 versions
AI Vulin, FM Stanley - Journal of Biological Chemistry, 2002 - ASBMB Plasminogen activator inhibitor-1 (PAI-1) is an important regulator of
fibrinolysis by its inhibition of both tissue-type and urokinase plasminogen
activators. PAI-1 levels are elevated in type II diabetes and this ... Cited by 17 - Related articles - BL Direct - All 5 versions
- ►nih.gov [PDF] M Motojima, T Ando, T Yoshioka - Biochemical Journal, 2000 - pubmedcentral.nih.gov Angiotensin II (Ang II) up-regulates plasminogen-activator in- hibitor type-1
(PAI-1) expression in mesangial cells to enhance extracellular matrix formation.
The proximal promoter region (bp k87 to k45) of the human PAI-1 gene ... Cited by 35 - Related articles - BL Direct - All 6 versions
- ►ahajournals.org YB Chen, JJ Billadello, DJ Schneider - Arteriosclerosis, thrombosis, and vascular biology, 2000 - Am Heart Assoc Abstract—The increased expression of plasminogen activator inhibitor type-1
(PAI-1) is associated with increased concentrations of fatty acids in blood and
may accelerate atherogenesis in diabetes. The present study was designed to ... Cited by 36 - Related articles - BL Direct - All 6 versions
F Carmassi, M Morale, L Ferrini, G Dell'Omo, M … - The American journal of medicine, 1999 - Elsevier Purpose: Plasma levels of plasminogen activator inhibitor-1 are increased in
obesity, hypertension, and diabetes. Their correlation with insulin levels
supports the hypothesis that hypofibrinolysis may affect the development of ... Cited by 43 - Related articles - BL Direct - All 8 versions
W Dichtl, MP Ares, M Stollenwerk, CM … - Thrombosis and haemostasis, 2000 - ncbi.nlm.nih.gov High plasma levels of plasminogen activator inhibitor-1 (PAI-1) are associated
with an increased risk of cardiovascular disease. There is also a close relation
between high plasma levels of PAI-1 and hypertriglyceridemia. Cell culture ... Cited by 18 - Related articles - All 2 versions
